These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37868796)

  • 41. Automatic prediction of treatment outcomes in patients with diabetic macular edema using ensemble machine learning.
    Liu B; Zhang B; Hu Y; Cao D; Yang D; Wu Q; Hu Y; Yang J; Peng Q; Huang M; Zhong P; Dong X; Feng S; Li T; Lin H; Cai H; Yang X; Yu H
    Ann Transl Med; 2021 Jan; 9(1):43. PubMed ID: 33553336
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?
    Patel Y; Miller DM; Fung AE; Hill LF; Rosenfeld PJ
    Ophthalmol Retina; 2020 Feb; 4(2):141-147. PubMed ID: 31735634
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-world outcomes of anti-VEGF therapy in treatment-naïve neovascular age-related macular degeneration diagnosed on OCT angiography: the REVEAL study.
    Lupidi M; Schiavon S; Cerquaglia A; Fruttini D; Gujar R; Muzi A; Fiore T; Reibaldi M; Chhablani J; Cagini C
    Acta Ophthalmol; 2022 Jun; 100(4):e936-e942. PubMed ID: 34407298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
    JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration.
    Hikichi T
    Jpn J Ophthalmol; 2023 Nov; 67(6):652-656. PubMed ID: 37861941
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Post-operative visual outcomes based on morphological staging of idiopathic epiretinal membranes on OCT.
    Momin SNA; Choudhary RA; Siddiqui MAR; Hashmi S; Memon AS; Tayyab H
    Int J Ophthalmol; 2022; 15(12):1966-1970. PubMed ID: 36536979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A proof of concept study to evaluate the treatment response of aflibercept in wARMD using OCT-A (Canada study).
    Sodhi SK; Trimboli C; Kalaichandran S; Pereira A; Choudhry N
    Int Ophthalmol; 2021 May; 41(5):1697-1708. PubMed ID: 33550508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration.
    Kishi M; Miki A; Kamimura A; Okuda M; Matsumiya W; Imai H; Kusuhara S; Nakamura M
    J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of Intra- and Subretinal Fluid on Vision Based on Volume Quantification in the HARBOR Trial.
    Riedl S; Vogl WD; Waldstein SM; Schmidt-Erfurth U; Bogunović H
    Ophthalmol Retina; 2022 Apr; 6(4):291-297. PubMed ID: 34922038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
    Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M
    Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Abdelfattah NS; Lei J; Shi Y; Marion KM; Morgenthien E; Gune S; Balasubramanian S
    Ophthalmology; 2020 Oct; 127(10):1360-1370. PubMed ID: 32402555
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of visual and anatomical outcomes for neovascular age-related macular degeneration treated with bevacizumab.
    Ma C; Bai L; Lei C; Wu C; Shi Q; Hu F; Hao Z; Ma LE
    Biomed Rep; 2015 Jul; 3(4):503-508. PubMed ID: 26171156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. OCT Predictors of 3-Year Visual Outcome for Type 3 Macular Neovascularization.
    Sacconi R; Forte P; Tombolini B; Grosso D; Fantaguzzi F; Pina A; Querques L; Bandello F; Querques G
    Ophthalmol Retina; 2022 Jul; 6(7):586-594. PubMed ID: 35227948
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
    Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
    Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
    Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Central Macular Fluid Volume With Central Subfield Thickness in Patients With Diabetic Macular Edema Using Optical Coherence Tomography Angiography.
    You QS; Tsuboi K; Guo Y; Wang J; Flaxel CJ; Bailey ST; Huang D; Jia Y; Hwang TS
    JAMA Ophthalmol; 2021 Jul; 139(7):734-741. PubMed ID: 33983385
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anatomic Biomarkers of Macular Edema Associated with Retinal Vein Occlusion.
    Ciulla TA; Kapik B; Hu A; Harris A; Ip MS; Blodi B
    Ophthalmol Retina; 2022 Dec; 6(12):1206-1220. PubMed ID: 35781069
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.
    Kriechbaum K; Prager F; Geitzenauer W; Benesch T; Schütze C; Simader C; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2415-21. PubMed ID: 19744723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.
    Gallardo M; Munk MR; Kurmann T; De Zanet S; Mosinska A; Karagoz IK; Zinkernagel MS; Wolf S; Sznitman R
    Ophthalmol Retina; 2021 Jul; 5(7):604-624. PubMed ID: 33971352
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Deep-Learning Algorithm to Predict Short-Term Progression to Geographic Atrophy on Spectral-Domain Optical Coherence Tomography.
    Dow ER; Jeong HK; Katz EA; Toth CA; Wang D; Lee T; Kuo D; Allingham MJ; Hadziahmetovic M; Mettu PS; Schuman S; Carin L; Keane PA; Henao R; Lad EM
    JAMA Ophthalmol; 2023 Nov; 141(11):1052-1061. PubMed ID: 37856139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.